Read More Pharma Industry News Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation? Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence. byVenkateshJuly 2, 2026